Navigation Links
Novo Nordisk Intends to Appeal Adverse Ruling in Prandin® (repaglinide) Patent Case
Date:1/19/2011

PRINCETON, N.J., Jan. 19, 2011 /PRNewswire/ -- Today, Novo Nordisk announced that Judge Avern Cohn of the US District Court for the Eastern District of Michigan issued an adverse ruling in a patent litigation case regarding Novo Nordisk's US Patent No. 6,677,358. The district court ruled that the patent, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable. Novo Nordisk markets repaglinide under the trade name Prandin® and a fixed dose repaglinide/metformin tablet under the trade name PrandiMet®. The district court ruling has the potential to facilitate launch of a generic repaglinide. At present, it is unclear whether or when a generic version of Prandin® or PrandiMet® will be available in the U.S. market. Novo Nordisk intends to appeal this ruling and is evaluating its best options for doing so.

(Logo: http://photos.prnewswire.com/prnh/20020404/NVOLOGO)

"We are disappointed with today's ruling. We believe that it is contrary to the evidence and we intend to appeal the ruling," says Jesper Brandgaard, executive vice president and chief financial officer of Novo Nordisk.

For the first nine months of 2010, US sales of Prandin® and PrandiMet® amounted to USD 134 million.

Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 30,100 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.


'/>"/>
SOURCE Novo Nordisk
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile
2. Novo Nordisk A/S and Emisphere Technologies, Inc. Announce License Agreement to Develop Oral Formulation of Insulin for Diabetes
3. Novo Nordisk and Chip Ganassi Racing Team Up for 2011 IZOD IndyCar Series
4. Novo Nordisk and Entertainment Industries Council Work Together to Improve Public Education and Awareness about Diabetes Epidemic
5. Novo Nordisk to Invest $73m in Expansion of U.S. Manufacturing Facility
6. Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg
7. Novo Nordisk Addresses Innovation in Diabetes Care in Second Issue of Industry Resource for Information on Diabetes and Chronic Disease
8. Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp
9. Novo Nordisk Awards More Than $300,000 in Grants to Support Education and Community Health Programs
10. Novo Nordisk partners with international scientific community for Victoza(R) cardiovascular outcomes trial
11. Novo Nordisk Awarded Department of Veterans Affairs National Insulin Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... , Jan. 12, 2017   JDRF ... diabetes (T1D) research, is pleased to announce that ... the Centers for Medicare & Medicaid Services (CMS) ... by the FDA for use in making diabetes ... step toward making them eligible for coverage under ...
(Date:1/13/2017)... DUBLIN , Jan 13, 2017 Research ... - Heat Map and Analysis" report to their offering. ... Cystic fibrosis (CF) ... patient inheriting a faulty cystic fibroses transmembrane conductance regulator (CFTR) gene ... on the body,s epithelial cells, and result in the buildup of ...
(Date:1/13/2017)... , Jan. 12, 2017  Albertsons Companies ... Accreditation Commission for Health Care (ACHC) for its ... national food and drug chain with this accreditation ... pharmacy patients. Accreditation by ACHC reflects ... standards to facilitate a higher level of performance ...
Breaking Medicine Technology:
(Date:1/16/2017)... CA (PRWEB) , ... January 16, 2017 , ... ... manuscript in the Aesthetic Surgery Journal , the official journal of The ... conducted on lower eyelid retraction surgery. The procedure is designed to correct drooping, ...
(Date:1/16/2017)... ... , ... NexTec Group has been selected as a member of the Bob ... in the field of midmarket financial software. , Members of the VAR Stars were ... not based on revenue and those firms chosen represent a wide range of size ...
(Date:1/15/2017)... ... January 15, 2017 , ... "On Tour is a music themed slideshow production ... said Christina Austin - CEO of Pixel Film Studios. , On Tour’s new ... style and animation of their slideshows. Place each slide on top of another slide ...
(Date:1/14/2017)... MN (PRWEB) , ... January 14, 2017 , ... ... present the distinctions among their expanding line of activated charcoal products. With more ... the importance of categorizing their products according to how they cater to specific ...
(Date:1/13/2017)... , ... January 13, 2017 , ... The 18th European ... America hotel on March 3-4, 2017. This Congress is expertly designed to meet ... management of patients with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor ...
Breaking Medicine News(10 mins):